Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $37.56.
Several equities analysts have issued reports on the stock. JMP Securities decreased their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank Of Canada decreased their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Needham & Company LLC restated a "buy" rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. Finally, The Goldman Sachs Group decreased their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th.
Check Out Our Latest Stock Analysis on VRDN
Viridian Therapeutics Trading Up 1.0%
NASDAQ VRDN traded up $0.16 on Monday, reaching $16.05. The stock had a trading volume of 807,335 shares, compared to its average volume of 1,151,772. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -4.17 and a beta of 0.39. The company has a quick ratio of 19.49, a current ratio of 19.49 and a debt-to-equity ratio of 0.05. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $27.20. The stock has a fifty day moving average price of $14.11 and a two-hundred day moving average price of $15.48.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 102,092.39% and a negative return on equity of 70.61%. The company's revenue was up .0% on a year-over-year basis. As a group, sell-side analysts forecast that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.
Hedge Funds Weigh In On Viridian Therapeutics
A number of hedge funds have recently made changes to their positions in VRDN. Foresite Capital Management VI LLC purchased a new stake in Viridian Therapeutics during the 4th quarter worth $38,000. Amalgamated Bank increased its stake in Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after buying an additional 840 shares during the period. AlphaQuest LLC increased its stake in Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares during the period. Summit Investment Advisors Inc. increased its stake in Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after buying an additional 1,516 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Viridian Therapeutics by 3,892.9% in the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock worth $114,000 after purchasing an additional 8,214 shares during the last quarter.
Viridian Therapeutics Company Profile
(
Get Free ReportViridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
See Also

Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.